Dr. reddy's laboratories presents preclinical data at sitc 2020 demonstrating significant improvement in tumor growth inhibition and overall survival through a combination of e7777 (denileukin diftitox) and an immune checkpoint inhibitor

Hyderabad, india & princeton, n.j.--(business wire)--dr. reddy's laboratories ltd. (bse: 500124, nse: drreddy, nyse: rdy, along with its subsidiaries together referred to as “dr. reddy's”) today announced a preclinical data presentation for e7777 (denileukin diftitox), its engineered il-2-diphtheria toxin fusion protein, at the society for immunotherapy of cancer (sitc) 35th anniversary annual meeting, being held virtually. dr. anil namboodiripad, senior vice president and head of dr. reddy's p
RDY Ratings Summary
RDY Quant Ranking